Otsuka Pharmaceutical moved into experimental psychiatry by announcing a $700 million acquisition of Transcend Therapeutics through its U.S. subsidiary, Otsuka America. The deal could add up to $525 million in milestones tied to sales performance, with closing expected between April and late June. Transcend’s lead asset, TSND-201 (methylone), is designed to rapidly enhance neuroplasticity by engaging specific transporter proteins linked to serotonin, norepinephrine, and dopamine signaling. The company positions the approach as distinct from classic MDMA-like mechanisms, including an emphasis that it does not target the serotonin receptor tied to hallucinogenic effects. The rationale is reinforced by recently published mid-stage data in JAMA Psychiatry in adults with PTSD. Transcend is now enrolling a Phase 3 program in the U.S., and Otsuka is effectively underwriting a late-stage development push behind a potentially paradigm-shifting PTSD therapy.